Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.60 |
| ▸ | BCL9 | O00512 | 3/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 6/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152391 | 0.88 | MGLL (0.58) | MGLLBCL9CTNNB1C5AR1PTPN1 | |
| SCHEMBL18165102 | 0.85 | MGLL (0.52) | MGLLBCL9CTNNB1C5AR1PTPN1 | |
| SCHEMBL20021936 | 0.81 | BCL9 (0.53) | BCL9CTNNB1MAPT | |
| SCHEMBL20025818 | 0.81 | BCL9 (0.48) | MGLLBCL9CTNNB1C5AR1ALDH1A1 | |
| SCHEMBL20021934 | 0.78 | BCL9 (0.55) | BCL9CTNNB1C5AR1MAPT | |
| SCHEMBL9126984 | 0.78 | MGLL (0.57) | MGLLC5AR1PTPN1SMN1; SMN2ENPP2 | |
| SCHEMBL27815058 | 0.77 | MGLL (0.71) | MGLLSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL21062557 | 0.75 | MGLL (0.52) | MGLLBCL9CTNNB1PTPN1SMN1; SMN2 | |
| SCHEMBL21062556 | 0.75 | MGLL (0.52) | MGLLBCL9CTNNB1PTPN1SMN1; SMN2 | |
| SCHEMBL705457 | 0.74 | MGLL (0.58) | MGLLPTPN1SMN1; SMN2ENPP2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | MGLL 3288/4885BCL9 1/4885CTNNB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.